Nondialyzable versus Dialyzable β-Blockers in Hemodialysis
Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2506-2516
DOI: 10.1681/asn.0000001147 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 20.05.2026. Verfasst von Ali Etemadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Renal Dialysis, Cardiovascular Diseases, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ASN Foundation for Kidney Research.
Abstract (Originalsprache)
Key Points Many major adverse cardiovascular events happen within the first 6 months after hemodialysis initiation. Using nondialyzable β -blockers at hemodialysis initiation was associated with fewer cardiovascular events than dialyzable β -blockers.
Background
How β -blocker dialyzability affects cardiovascular outcomes in patients receiving hemodialysis remains unclear. Previous observational studies show conflicting results, and conducting clinical trials in this population has proven challenging. This uncertainty has contributed to substantial variation in β -blocker prescribing patterns across regions and clinicians.
Methods
Using data from the United States Renal Data System, we identified patients receiving β -blockers on the day of starting hemodialysis and classified them into nondialyzable and dialyzable exposure groups. Geographical variations in nondialyzable and dialyzable β -blocker prescription rates across neighboring regions in each state were leveraged as an instrumental variable. The treatment effect of nondialyzable versus dialyzable β -blockers on major adverse cardiovascular events (MACE) at 6 months, 1 year, and 3 years was evaluated using instrumental variable g -estimation methods for survival outcomes. MACE comprised myocardial infarction, stroke, and all-cause mortality.
Results
The cohort of 40,313 participants from 41 US states experienced 25,720 MACE over the 3-year follow-up period (median years [interquartile range], 1.4 [0.4–3.0]), with more than 42% occurring during the first 6 months after hemodialysis initiation. The instrumental variable met all statistical assumptions. Nondialyzable β -blockers were associated with significantly lower risk of MACE at all three follow-up time points compared with dialyzable β -blockers (hazard ratios [95% confidence intervals], 0.82 [0.74 to 0.90], 0.85 [0.79 to 0.92], and 0.90 [0.85 to 0.96], respectively). Similar patterns were observed for each separate component of MACE.
Conclusions
The use of nondialyzable β -blockers compared with dialyzable β -blockers was associated with a lower risk of MACE during all time points, including the early, high-risk period in the 6 months following hemodialysis initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Stanford University, Stanford, California.
- Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
ORCID-Profile: Ali Etemadi, Sai Liu, Maria E Montez-Rath, Tara I Chang
Förderung
- ASN Foundation for Kidney Research
Zitieren
APA
Etemadi, A., Liu, S., Winkelmayer, W. C., Montez-Rath, M. E., & Chang, T. I. (2026). Nondialyzable versus Dialyzable β-Blockers in Hemodialysis. Journal of the American Society of Nephrology, 37(11), 2506-2516. https://doi.org/10.1681/asn.0000001147
Vancouver
Etemadi A, Liu S, Winkelmayer WC, Montez-Rath ME, Chang TI. Nondialyzable versus Dialyzable β-Blockers in Hemodialysis. Journal of the American Society of Nephrology. 2026;37(11):2506-2516. doi:10.1681/asn.0000001147
BibTeX
@article{Etemadi2026,
author = {Etemadi, Ali and Liu, Sai and Winkelmayer, Wolfgang C and Montez-Rath, Maria E and Chang, Tara I},
title = {Nondialyzable versus Dialyzable β-Blockers in Hemodialysis},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {11},
pages = {2506--2516},
doi = {10.1681/asn.0000001147}
}
EUVIMED